Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

• Market Cap: ₹547.23M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): -0.15
• Revenue Growth: -22.42%
• EPS Growth: 21.83%
• Country: IN
• Employees: 607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.00
• Shares Outstanding: 82,913,910
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.04
• Price to Book (P/B): -1.17
• Price to Sales (P/S): 0.35
• P/FCF Ratio: -4.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: ₹8.00 ▲(61.62% Upside)
• Action: Downgraded Date: 01/21/26
• Date: Action: Downgraded 01/21/26

The score is driven primarily by severe financial weakness (declining revenue, collapsing margins, ongoing losses, negative equity, and negative cash flows). Technical indicators also lean bearish with price below key moving averages and a negative MACD. Valuation is not supportive due to the negative P/E and no indicated dividend yield.

Positive Factors

Diversified product and end-market mix

Vivimed's operations across APIs, finished dosage forms and specialty chemicals provide multiple, structurally different revenue streams. This diversification reduces single-market exposure and supports resilience across demand cycles in pharma and personal care over the next several months.

Manufacturing and contract-manufacturing capabilities

Established development and manufacturing capabilities plus contract manufacturing partnerships create durable revenue channels. Long-term CMO relationships and in-house production capacity are tangible assets that support order continuity and higher switching costs for clients.

International exposure and licensing potential

Access to export markets and licensing opportunities diversifies demand and reduces dependence on domestic cycles. International channels and licensing can sustain revenue recovery opportunities and provide pricing arbitrage and scale benefits over 2-6 months.

Negative Factors

Sustained revenue decline

A persistent top-line contraction signals loss of market share or demand that is unlikely to reverse quickly. Falling revenues erode operating leverage, constrain reinvestment capacity, and make multi-month recovery dependent on material commercial or product shifts.

Collapsing margins and ongoing losses

Dramatic margin erosion and persistent negative operating and net margins indicate structural pricing, cost, or product-mix problems. Margin recovery is essential for sustainable cash generation; without it the company faces prolonged profitability headwinds.

Balance-sheet strain and negative cash flows

Negative equity, high leverage metrics and steeply deteriorating free cash flow imply solvency and liquidity risk. These structural financial weaknesses limit strategic flexibility, increase refinancing risk, and may force dilutive or restrictive measures in the medium term.

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Vivimed Labs generates revenue primarily through the sale of its pharmaceutical products, which include APIs and finished formulations for various therapeutic segments. Additionally, the company earns income from its specialty chemicals division, which supplies products to the personal care and cosmetics industries, as well as other industrial sectors. Key revenue streams include contract manufacturing partnerships and collaborations with major pharmaceutical companies, enabling Vivimed to leverage its manufacturing capabilities and expertise. The company may also benefit from licensing agreements and export sales in various international markets, contributing to its overall financial performance.

Vivimed Labs Limited Financial Statement Overview

Summary

Very weak fundamentals: revenue declined sharply (most recent revenue growth -18.75%), profitability collapsed (gross margin fell from 58.85% in 2021 to 6.71% in 2025) with ongoing negative net/EBIT/EBITDA margins, the balance sheet shows negative equity and high leverage risk (debt-to-equity -10.70 in 2025), and cash flows are negative with steep free-cash-flow deterioration (FCF growth -145.86% in 2025).

Income Statement

Vivimed Labs Limited has faced significant challenges in its income statement metrics. The company has experienced a consistent decline in revenue over the years, with a notable revenue growth rate of -18.75% in the most recent year. Gross profit margins have deteriorated sharply from 58.85% in 2021 to 6.71% in 2025, indicating a severe decline in profitability. Net profit margins have remained negative, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and financial distress.

Balance Sheet

The balance sheet of Vivimed Labs Limited reveals a precarious financial position. The company has a negative stockholders' equity in recent years, resulting in an alarming debt-to-equity ratio of -10.70 in 2025. This indicates a high level of financial leverage and potential solvency issues. The return on equity is negative, reflecting the company's inability to generate returns for shareholders. The equity ratio has also been negative, underscoring the company's reliance on debt financing.

Cash Flow

Vivimed Labs Limited's cash flow metrics show significant challenges. The company has experienced negative operating and free cash flows in recent years, with a free cash flow growth rate of -145.86% in 2025. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. The free cash flow to net income ratio is positive, but this is due to the negative net income, which is not a positive indicator of financial health.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	676.14M	1.16B	1.49B	1.87B	2.37B	8.61B
Gross Profit	229.66M	77.98M	705.71M	-928.65M	838.04M	5.07B
EBITDA	11.07M	-86.77M	-246.69M	-1.86B	-67.91M	336.05M
Net Income	-183.94M	-319.61M	-454.46M	-3.29B	-676.50M	-777.95M
Balance Sheet
Total Assets	9.24B	9.21B	9.51B	9.88B	12.66B	12.89B
Cash, Cash Equivalents and Short-Term Investments	489.84M	7.08M	717.79M	37.62M	71.84M	64.31M
Total Debt	3.84B	3.76B	3.79B	3.81B	2.78B	2.53B
Total Liabilities	9.72B	9.56B	9.56B	9.49B	9.02B	8.58B
Stockholders Equity	-479.63M	-351.69M	-54.61M	394.23M	3.64B	4.32B
Cash Flow
Free Cash Flow	-161.74M	-86.28M	-260.30M	303.54M	-6.75B	5.67B
Operating Cash Flow	-161.74M	-40.97M	-239.91M	138.12M	-6.58B	5.67B
Investing Cash Flow	112.50M	-45.31M	282.88M	-49.68M	5.23B	4.04B
Financing Cash Flow	54.87M	73.10M	-60.32M	-162.44M	-103.80M	-10.15B

Vivimed Labs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Negative. The current price of 4.95 is below the 20-day moving average (MA) of 7.32, below the 50-day MA of 8.42, and below the 200-day MA of 6.54, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 37.45 is Neutral, neither overbought nor oversold. The STOCH value of 21.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIVIMEDLAB.

Vivimed Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOFILCHEM	63 Neutral	₹487.73M	172.45	―	―	36.76%	433.63%
BALAXI	62 Neutral	₹975.52M	111.96	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	44 Neutral	₹358.72M	-4.63	―	―	-20.40%	-59.20%
VIVIMEDLAB	39 Underperform	₹547.23M	-1.41	―	―	-22.42%	21.83%

Vivimed Labs Limited Corporate Events

Vivimed Labs Posts Sharp Revenue Drop and Quarterly Loss in Q3 FY26

Vivimed Labs Limited reported its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, following approval by its board of directors. The filings, made in compliance with India’s listing regulations, included a limited review report from the statutory auditors, indicating that the company continues to meet its periodic disclosure obligations to stock exchanges and investors.

The latest numbers show a sharp year-on-year decline in quarterly revenue, which fell to about a tenth of the level reported in the same period a year earlier, and the company swung to a net loss for the quarter and nine-month period. The deterioration in performance, driven by lower operating income and persistent cost pressures, underlines continuing operational challenges for Vivimed Labs and may heighten concerns among shareholders and creditors about its near-term earnings trajectory and financial resilience.